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Abstract: Parkinson’s disease (PD) is one of the most common neurodegenerative diseases. The
mechanisms underlying PD remain to be fully elucidated, and research into treatments for this
condition is ongoing. Recent advances in genetic research have shed light on the mechanisms
underlying PD. In this study, we used PD and control mesenchymal stem cells (MSCs) obtained from
adipose tissues to confirm the differences between groups at the cellular and molecular levels. The
results revealed that in PD MSCs, cell viability was clearly lower, and the rate of cell senescence
was higher compared to the controls. Next, to compare the gene expression in PD and control cells,
transcriptome analysis was performed. Genes in pathways, including extracellular matrix (ECM)
receptor interaction, P53 signaling, and focal adhesion, were down-regulated in PD. Among genes
related to ECM receptor interaction, RELN gene expression was markedly decreased in PD cells;
however, after being treated with recombinant Reelin protein, a significant increase in cell viability
and a decrease in α-Synuclein aggregation and cell senescence were observed. In conclusion, Reelin
affects PD by positively influencing the cell characteristics. Our findings will facilitate research into
new treatments for PD.
Keywords: parkinson’s disease; transcriptome analysis; extracellular matrix-receptor related
genes; Reelin
1. Introduction
Parkinson’s disease (PD) is a neurodegenerative disorder caused by the gradual dete-
rioration of midbrain dopaminergic (DA) neurons in the substantia nigra pars compacta.
Changes in DA cells lead to tremor and rigidity, and induce a slow decline of the extrapyra-
midal motor system. Despite this, treatments for PD and its underlying pathogenesis
remain understudied [1]. The main pathogenic effect of PD is the degeneration of DA
neurons in the substantia nigra pars compacta; however, there is evidence that tissues
in other physiological systems contribute to the symptoms of PD [2]. Gene expression
profiling (GEP) research has consistently detected problems with mitochondria or protein
processing in PD, revealing potential new biomarkers for the disease. Previous studies
conducted a comparison of the biological pathways identified from microarray study data,
which was an effective method to solve interstudy variability in gene level analyses [3,4].
Postmortem GEP studies conducted on the substantia nigra of PD patients have implicated
the number of biological pathways, which also function in non-nigral tissues [5].
Genes 2021, 12, 1066. https://doi.org/10.3390/genes12071066 https://www.mdpi.com/journal/genes
Genes 2021, 12, 1066 2 of 14
Neurodegeneration in non-nigral tissues contributes to the non-motor symptoms
of PD, which include dementia and depression. Dopamine replacement therapy is less
effective in combating these non-motor symptoms relative to motor symptoms [6,7]. There-
fore, research on the neuronal degeneration of non-nigral tissue has potential, not only to
deepen the understanding of PD pathogenesis, but also to provide information useful for
the development of treatment for non-motor symptoms.
Mesenchymal stem cells (MSCs) are multipotent cells that can differentiate into neuron-
like cells, and they have been studied as part of potential therapy for PD [8,9]. MSCs are also
used to determine differential gene expression and clustering analysis via transcriptome
analysis without any ethical issues and low donor-site morbidity so that adipose-derived
MSCs can be used as promising candidates for various clinical applications, representing
human cell model [8,10,11]. However, MSCs get limited regenerative capacity depending
on the age, and it has low survival rate when used in PD patients as replacements for disease
neurons in the host [12–14]. We questioned what the differences would be in molecular
and cellular levels between the control and PD patient MSCs, and how to increase the
survival rate of MSCs. Since PD is an age-related neurodegenerative disease associated with
systemic problems, including inflammation, MSCs isolated from the abdominal adipose
tissue were used in our cell model for PD to conduct GEP investigation in this study [15].
Our results provide important data pertinent to research of the mechanisms underlying
PD and potential treatment targets [16]. Particularly, our study investigated the biological
pathway associated with extracellular matrix (ECM) found by transcriptome analysis in
PD. There are studies showing that ECM molecules and their receptor expression level
alternations are associated with central nervous system diseases, including the human
brain aging with PD [17–19]. Transcriptional- and translational-level regulation of ECM-
degrading enzymes, such as matrix metalloproteinases, can affect disease pathogenesis [18].
Similarly, our research using transcriptome analysis to examine specific changes at the gene
expression level identified ECM-associated pathways as implicated in PD.
2. Materials and Methods
2.1. Subjects
This study was approved by the Ethics Committee, and the participants signed in-
formed consent prior to the study. Human adipose-derived MSCs were obtained from
a 68-year-old female volunteer as a control; moreover, the patient-derived samples were
obtained with the agreement of the participants, who provided his or her written informed
consent. The Institutional Review Board of Severance Hospital, Yonsei University Health
System approved this consent procedure and the entire study (no. 4-2008-0277, 4-2012-
0028). An age-matched female patient with PD, aged 68 years, who was not receiving any
pharmacological treatment, was included in this study. The patient was recruited at the
Rehabilitation Institute of Neuromuscular Disease. The patient with PD included in this
study did not show any signs of infection before undergoing liposuction.
2.2. Cell Culture
MSCs were cultured from the abdominal adipose tissue samples from a control patient
and patient with PD. The biopsy sample was transferred to a culture dish in low glucose
Dulbecco’s modified Eagle’s medium (DMEM) containing 10% fetal bovine serum (FBS)
and penicillin/streptomycin (P/S). For human neuroblastoma cells, SH-SY5Y cells were
cultured with Dulbecco’s Modified Eagle Medium/Nutrient Mixture F-12 (DMEM/F12)
containing 10% FBS and 1% P/S. Cells were incubated in a humidified 5% carbon dioxide
atmosphere at 37 ◦C.
2.3. Cell Viability and Senescence Analysis
For analysis of cell viability, MSCs were seeded in 6-well plates (103 cells/well) in
DMEM containing 10% FBS and P/S. The number of cells per plate was determined
from counts obtained using an ADAM automatic cell counter 2, 4, 6, and 8 days after
Genes 2021, 12, 1066 3 of 14
plating, as described in the manufacturer’s protocol (NanoEnTek Inc., Seoul, Korea). Flow
cytometric analysis of cellular senescence was performed using a Quantitative Cellular
Senescence Assay Kit (Cell Biolabs, San Diego, CA, USA). Briefly, MSCs were treated
with pretreatment solution at 37 ◦C for 2 h. Next, senescence-associated β-galactosidase
(SA-β-gal) substrate solution was added to the cells for 4 h. Stained cells were washed
with Dulbecco’s phosphate-buffered saline (DPBS) and harvested by trypsinization. For
microscopy studies, MSCs were washed with DPBS, fixed for 15 min in fixing solution at
room temperature, briefly washed in DPBS, and then incubated with SA-β-Gal substrate
solution at 37 ◦C without carbon dioxide and with protection from light for 16 h. Blue-
stained cells were analyzed by light microscopy.
2.4. RNA Preparation
Total RNA was isolated from the cultured MSCs obtained from a patient with PD
and controls using Trizol (Invitrogen Life Technologies, Carlsbad, CA, USA) according to
the manufacturer’s instructions [20]. RNA purity was evaluated using an Agilent 2100
Bioanalyzer (Agilent Technologies, Palo Alto, CA, USA), and the A260/A280 ratio was
measured for quality control analysis. RNA integrity was evaluated by visual evaluation
of the 28S:18S rRNA ratio using gel electrophoresis.
2.5. RNA Sequencing Transcriptome Analysis
RNA sequencing (RNA-seq) and transcriptome data analysis were performed by
Macrogen Inc. (Seoul, Korea). mRNA libraries for cluster generation were prepared using
the reagents provided in the Illumina TruSeq™ RNA Sample Preparation Kit [21]. Tran-
scriptome analysis comprised RNA-seq experiments and data handling [22]. RNA-seq
experiments involved TruSeq mRNA library construction, which included eight steps:
(1) purify and fragment mRNA, (2) synthesize first strand cDNA, (3) synthesize second
strand cDNA, (4) perform end repair, (5) adenylate 3’ ends (i.e., add a single adenosine
residue), (6) ligate adapters, (7) enrich DNA fragments, and (8) validate the enriched li-
brary. First, poly-Adenine containing mRNA molecules were purified using poly-Thymine
oligonucleotide-conjugated magnetic beads. After purification, using divalent cations at
raised temperature (94 ◦C, 8 min), the mRNA was sheared into small fragments. First
strand cDNA was generated from the cleaved RNA fragments using random hexamer
primers and reverse transcriptase. The cDNA fragments were then subjected to an end
repair process using an end repair mix, which added a single “Adenine” nucleotide, fol-
lowed by adapter ligation. On the 3′ end of the adapter, there was a corresponding single
“Thymine” nucleotide, which provided a paired overhang for binding to the adapter to the
fragment. To create the final cDNA library, the products were purified and enriched by
polymerase chain reaction (PCR) [23].
Illumina uses a unique reaction, referred to as “bridged” amplification, which occurs
on the surface of the flow cell. The flow cell, which contains millions of unique clusters,
is loaded into the HiSeq 2000 for automated cycles of imaging and extension. Solexa’s
Sequencing-by-Synthesis utilizes four proprietary nucleotides with reversible fluorophore
and termination properties. Every individual sequencing cycle occurs in the presence of
all four nucleotides, leading to superior accuracy relative to methods in which only one
nucleotide is present in the reaction mix [24].
To evaluate expression levels, RNA-seq reads were mapped to the human genome
and transcript counts were calculated at the gene level. Data analysis was performed using
TopHat and Cufflinks. TopHat is a fast splice junction mapper for RNA-seq reads. Using
an ultra-high-throughput short read aligner known as Bowtie, TopHat aligns the RNA-seq
reads to mammalian-sized genomes. Subsequently, TopHat analyzes the mapping results
to identify the splice junctions between exons. Cufflink tests for differential expression
and regulation in RNA-seq samples, in addition to assembling transcripts and estimating
their abundance. Transcripts with fold induction <2 and Benjamini-Hochberg adjusted
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p-values < 0.05 were considered significantly different between control and PD samples,
and were included in the downstream analysis.
2.6. Kyoto Encyclopedia of Genes and Genomes Pathway Analysis
For analysis, the database for annotation, visualization, and integrated discovery
(DAVID) software (http://david.abcc.ncifcrf.gov/, accessed on 25 November 2015) [25]
and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways [26,27] were selected.
Using the DAVID software, our study found which pathways were down-regulated in
PD cell.
2.7. Reverse Transcription and Quantitative Reverse Transcription Polymerase Chain Reaction
This study additionally performed reverse transcription polymerase chain reaction
(RT-PCR) to validate the results from the transcriptome analysis. The RT-PCR of genes
were components of significantly down-regulated KEGG pathways, which is related to
neuronal protection. Quantitative real-time polymerase chain reaction (qRT-PCR) was
conducted, as described in detail in a previous study [28]. For additional validation, qRT-
PCR was performed in triplicate on a Light Cycler 480 (Roche Applied Science, Mannheim,
Germany) using the Light Cycler 480 SYBR Green master mix (Roche Applied Science), and
thermocycler conditions of 10 min template preincubation step at 95 ◦C, followed by 40
cycles at 95 ◦C for 10 s, 60 ◦C for 10 s, and 72 ◦C for 10 s, followed by melting curve analysis,
beginning at 95 ◦C for 5 s, followed by 1 min at 60 ◦C. The following primers were used for
qRT-PCR: human RELN forward, 5′- TAC AGC GTC AAC AAC GGG AT-3′; RELN reverse,
5′- CGA CCT CCA CAT GGT CCA AA -3′ (190 base pair); human GAPDH forward, 5′-
AAG GGT CAT CAT CTC TGC CC -3′; human GAPDH reverse, 5′-GTG AGT GCA TGG
ACT GTG GT-3′ (180 base pair). The specificity of amplification products was confirmed by
melting curve analysis, where all samples generated a distinct single sharp peak with the
expected melting temperature. A distinct single peak indicates that a single DNA sequence
was amplified during qRT-PCR. The glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
gene was used as the internal control. The expression level of each gene of interest was
determined using the 2−∆∆Ct method. Specific primers were used for both RT-PCR and
RT-qPCR (Table 1).
Table 1. Kyoto Encyclopedia of Genes and Genomes pathways enriched for Parkinson’s disease down-regulated genes,
generated using the Database for Annotation, Visualization and Integrated Discovery.
KEGG Pathway Count % p-Value Genes
ECM-receptor interaction 10 0.120 0.007 CD36, ITGA5, LAMA5, ITGA8, COL6A3,COL6A2, ITGA1, DAG1, RELN, COL5A3
P53 signaling pathway 8 0.096 0.021 STEAP3, ZMAT3, CD82, BAX, SHISA5,MDM2, CCNG2, GADD45A
Arrhythmogenic right
ventricular cardiomyopathy 8 0.096 0.037
ITGA5, ITGA8, ITGA1, DAG1, GJA1,
CACNB3, TCF7L2, TCF7L1
Focal adhesion 15 0.181 0.038
CAV1, TLN1, ITGA1, COL5A3, CAPN2,
MYL9, DOCK1, LAMA5, ITGA5, ITGA8,
COL6A3, COL6A2, PDGFRB, RELN, ZYX
Endocytosis 14 0.168 0.041
GIT1, ARFGAP1, CHMP2A, PLD1, ERBB3,
RUFY1, ASAP3, EPS15, FAM125A, AP2A1,
VPS24, VPS4A, MDM2, VPS28
2.8. Western Blot Analysis
For immunoblot analysis, the cells were collected and lysed with lysis buffer, con-
sisting of 10 mM Tris-HCl pH 7.4, 150 mM NaCl, 5 mM EDTA, 0.5% NP-40, Protease
inhibitor cocktail (Cell signaling technology, Beverly, CA, USA), and Phosphatase inhibitor
cocktail (GenDEPOT, Katy, TX, USA). The cell lysates were centrifuged at 18,000× g for
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15 min. The supernatant was collected, and protein concentrations were determined by
Bradford assay (Biorad, Hercules, CA, USA). Proteins were incubated in the anti-Reelin
(Santacruz, Santa Rosa, TX, USA) for 4 h at 4 ◦C, following by the addition of protein G
sepharose 4 fast flow beads (Sigma, Marietta, GA, USA) overnight at 4 ◦C. After that, the
immunocomplexes were washed with lysis buffer, and then denatured by adding 2× LDS
sample buffer (Invitrogen, Carlsbad, CA, USA), and boiled at 100 ◦C for less than 3 min.
For immunoblotting, the samples were separated on SDS-PAGE gels and transferred to
the PVDF (Millipore) membrane. Membranes were blocked for 1 h at room temperature
in 5% bovine serum albumin or 5% skim milk in Tris-buffered saline with 0.1% Tween 20
detergent (TBST, Biosesang), and then incubated with primary antibodies against Reelin
(Abcam) and β-actin (Santacruz) overnight at 4 ◦C. Membranes were washed in TBST and
incubated with anti-mouse HRP-conjugated secondary antibody (Santacruz) for 1 h at room
temperature. Membranes were washed in TBST and developed by the West-Q Pico ECL So-
lution (GenDEPOT). Chemi-luminescence signal was detected by the Chemi-iluminescence
Image Analyzer (LAS), and determined using the Multi Gauge V3.0 software. Protein
levels were normalized to β-actin levels from the same samples.
2.9. Preformed Fibril and Human Recombinant Reelin Treatment
SH-SY5Y cells were differentiated with retinoic acid (RA, 10 µM, Sigma, Marietta, GA,
USA) in high-glucose DMEM, containing 10% FBS and 1% P/S for 4 days. For preformed
fibril (PFF) and human recombinant Reelin (hr-Reelin) treatment, differentiated SH-SY5Y
cells were incubated with the medium, containing PFF (5 µg/mL, Stress Marq Biosciences
Inc., British Columbia, CA, USA) and hr-Reelin (R&D systems, Minneapolis, MN, USA),
for 4 days. For Thioflavin-S (Thio-S, Sigma) staining, SH-SY5Y cells were seeded onto
poly-D-lysine (0.1 mg/mL, Sigma)-coated 15 mm coverglasses, and then cultured. On days
in vitro 9 (DIV 9), fixed cells with 4% paraformaldehyde were incubated with 0.05% Thio-S
for 8 min at room temperature. After three times of 5 min washing with 80% ethanol, the
cells were rinsed three times with DPBS, and coverslipped using the antifade mounting
medium with DAPI (VECTASHIELD).
2.10. Statistical Analysis
Data are expressed as the mean ± standard deviation. Statistical analyses were
performed using the Statistical Package for Social Sciences (SPSS) version 23.0 or GraphPad
Prism (version 8.4.2, GraphPad software, La Jolla, CA, USA). Student’s t-test was used to
evaluate the statistical significance of differences in human MSC data. One-way ANOVA
followed by Bonferroni post hoc test was also used to determine the statistical significance
of differences for SH-SY5Y cell data; p-values < 0.05 were considered statistically significant.
3. Results
3.1. Cell Viability Was Decreased in Parkinson’s Disease
MSCs derived from a healthy individual and a patient with PD were cultured through
passages 4 to 8 in 6-well plates, and the number of cells counted after each passage, to
compare the proliferation rates between control and PD cells. Figure 1A shows that the
number of PD cells decreased rapidly at passage 5, while the number of MSCs reduced more
gradually in healthy control cells (Figure 1A). The numbers of PD cells were significantly
decreased compared to the control cells from passages 5 through 8 (p < 0.001). Furthermore,
differences between the proliferation of control and PD cells were clearly visible in serial
cell images (Figure 1B and Figure S1).
3.2. Cell Senescence Was Increased in Parkinson’s Disease
To compare the rates of cell senescence in each group, the number of cells stained
blue, representing SA-β-Gal activation, was counted. Microscopy images showed that
SA-β-Gal staining decreased in the control MSCs at passages 4 and 8 relative to PD
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cells (Figure 2A–D). In particular, cell senescence was increased at passage 8 in PD cells
(Figure 2D).
Figure 1. Comparison of cell viability in healthy control and Parkinson’s disease (PD) at each passage.
(A) Growth curves for mesenchymal stem cells (MSCs) from a PD patient and healthy control at
passages 4 to 8. n = 4 for each group. Mean ± S.E.M. (B) MSCs from control and PD subjects at
passage 8 (Student’s t-test, *** p < 0.001), scale bars = 50 µm.
Figure 2. Comparison of cell senescence-associated β-galactosidase (SA-β-Gal) staining between
control and Parkinson’s disease (PD) at passages 4 and 8 (A–D). SA-β-Gal activity in mesenchymal
stem cells (MSCs) from a PD patient and healthy control. (A) MSCs from a control subject at passage
4. (B) MSCs from a control subject at passage 8. (C) MSCs from a patient with PD at passage 4.
(D) MSCs from a patient with PD at passage 8. scale bars = 50 µm.
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3.3. Extracellular Matrix-Receptor Interaction-Related Genes Were Down-Regulated in
Parkinson’s Disease
RNA samples were prepared from the cultured control and PD MSCs. To determine
the influencing factors on the changes in cell viability and senescence, KEGG pathway
analysis of candidate genes from transcriptome data was conducted. KEGG pathway
results, generated using the DAVID program, identified which genes were involved in the
pathogenesis of PD. Among the various pathways, including ECM receptor interaction,
the P53 signaling, arrhythmogenic right ventricular cardiomyopathy, endocytosis, and
focal adhesion were significantly enriched for genes dysregulated in PD (Table 1; p < 0.05).
To elucidate the function of genes in the ECM-receptor interaction pathways, 10 down-
regulated genes were selected for comparison of RNA expression patterns in the control
and PD samples.
3.4. Both RELN mRNA and Reelin Protein Levels Were Down-Regulated in Parkinson’s Disease
Genes in the ECM-receptor interaction pathway were confirmed by analysis using the
DAVID program. PD was associated with changes to ECM-related factors, including 10
selected down-regulated genes, were marked with red stars (Figure 3).
Figure 3. Illustration of extracellular matrix (ECM)-receptor interactions described in the Kyoto
Encyclopedia of Genes and Genomes (KEGG) pathway. The KEGG pathway results generated using
the DAVID program are shown above. Parkinson’s disease is associated with changes to ECM-related
factors, including 10 selected down-regulated genes marked with red stars: CD36, ITGA5, LAMA5,
ITGA8, COL6A3, COL6A2, ITGA1, DAG1, RELN, COL5A3.
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RT-PCR of RELN mRNA and immunoblot for Reelin protein were subsequently
performed for further validation. RNA and protein expression levels of Reelin appeared
to be relatively low in PD compared to the control (Figure 4A,C). The selected gene and
protein were evaluated by qRT-PCR and Western blot for more accurate quantitative
analysis, respectively. RNA expression levels of RELN were significantly decreased at
both passage 4 and 8 in PD compared to the control (Figure 4B, p = 0.002 and <0.001,
respectively). The protein level of Reelin was also significantly decreased at passage 8 in
PD compared to the control (Figure 4D, p = 0.028).
Figure 4. Validation of extracellular matrix (ECM)-related adhesion molecule RELN mRNA and
Reelin protein levels. (A,C) Conformation of amplification using specific primer for RELN by RT-PCR
(A) and Reelin protein by Western blot (C). (B,D) Quantifications of relative RELN expression by
qRT-PCR (B) and Reelin protein level by Western blot (D). n = 3 (A,B) and n = 4 (C,D) for each
group. Mean ± S.E.M. Student’s t-test, * p < 0.05, ** p < 0.01, *** p < 0.001. Parkinson’s disease, PD;
Con, control.
3.5. Recombinant Reelin Protein Regulates Cell Viability and Senescence
To evaluate the effect of Reelin protein in both control and PD cells on cell prolifer-
ation, the experimental schedule in Figure 5A was followed, using two different protein
concentrations. The hr-Reelin protein (1 µg/mL) also significantly induced proliferation of
PD cells relative to DPBS treatment (Figure 5B, p = 0.0076). On culture with 2 µg/mL, hr-
Reelin protein led to significant induction of cell viability compared with DPBS treatment
(Figure 5C, p < 0.001).
To test whether Reelin could inhibit PD MSCs from getting in replicative senescence-
like state, known as the cell senescence, SA-β-Gal staining was performed and the cells
stained in blue were counted (Figure 6). In the PD group treated with 1 µg/mL, hr-Reelin
protein led to reduced SA-β-Gal-positive cells compared to the DPBS-treated control group
(Figure 6A). At 2 µg/mL, PD cells treated with hr-Reelin protein showed significantly
lower levels of senescence compared with DPBS-treated group control group. The hr-Reelin
protein-treated group contained less SA-β-Gal-positive cells relative to DPBS-treated cells
(p = 0.013); representative microscope images are presented in Figure 6B.
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Figure 5. Cell viability at passage 8 following treatment with human recombinant Reelin (hr-Reelin)
protein. (A) Experimental schedule and method for in vitro treatment with hr-Reelin proteins. (B,C)
Viability of control and Parkinson’s disease (PD) cells. (B) Treatment with phosphate-buffered saline
(DPBS) or hr-Reelin proteins at 1 µg/mL. (C) Treatment with DPBS or hr-Reelin proteins at 2 µg/mL.
n = 5 for control group, n = 4 for PD group. Mean ± S.E.M. Student’s t-test, ** p < 0.01; *** p < 0.001.
Figure 6. Cell senescence evaluated by β-galactosidase (SA-β-Gal) staining at passage 8 treated with human recombinant
Reelin (hr-Reelin) protein in Parkinson’s disease (PD) patient MSCs. (A) SA-β-Gal-positive cells were compared between
DPBS-treated group and 1 µg/mL or 2 µg/mL hr-Reelin-treated group. (B) Representative images. Scale bars= 50 µm. n = 6
for DPBS-treated group, n = 3 for hr-Reelin-treated groups. Mean ± S.E.M. Student’s t-test, * p < 0.05.
3.6. Recombinant Reelin Protein Attenuates α-Synuclein Aggragation in SH-SY5Y
To evaluate the effect of hr-Reelin protein, active α-Synuclein fibrils (PFFs) were added
to the differentiated human neuroblastoma (SH-SY5Y) cells to induce the cellular model of
PD (Figure 7A) [29,30]. Thioflavin-S (Thio-S) staining results showed that aggregated α-
Synuclein (α-Syn) formation with PFF treatment were significantly attenuated by hr-Reelin
protein treatment (either 1 µg/mL or 2 µg/mL) compared to the no hr-Reelin treatment
group (Figure 7B,C).
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Figure 7. Aggregated α-Synuclein protein formation was measured by Thioflavin-S (Thio-S) staining in preformed fibril
(PFF)-treated SH-SY5Y cells. (A) Differentiated SH-SY5Y cells were incubated with either PFF or human recombinant
Reelin (hr-Reelin) protein (1 µg/mL and 2 µg/mL). (B) Each of Thio-S-positive intensities were compared between groups.
(C) Representative images of (B). scale bars, 50 µm. Mean ± S.E.M. n = 52–95 cells in each group. One-way ANOVA
(Bonferroni post hoc test), *** p < 0.001. Retinoic acid; RA, days in vitro; DIV.
4. Discussion
Senescence can be observed at the systemic and cell levels. Overall, senescence is
associated with aging, and it also signifies a reduction in normal functions and an in-
creased vulnerability to stress [31]. The concept of cell senescence was first introduced
50 years ago, based on the finding that cells in culture can undergo only a limited num-
ber of divisions [32]. Senescence is a process of change that generally occurs without
apoptosis [33]. Cell senescence not only limits replicative ability but also changes cel-
lular metabolism, epigenetic regulation, and gene expression. Molecular changes, such
as alterations in morphology, growth factors and proteases, and cytokine secretion, that
occur during cell senescence, are referred to as the senescence-associated secretory phe-
notype [34]. Cell senescence is related both to aging and to neurodegenerative diseases,
such as Alzheimer’s disease (AD), PD, and frontotemporal dementia. Cell cycle arrest and
cell senescence are known to be some of the main causes for PD, which can activate cyclin-
dependent kinase (cdk5), induce neuronal inflammasomes, and lead neuronal cells to enter
a senescence-like state or death in PD [35–38]. In addition, cell senescence affects ECM
composition and content [39]. ASCs are a primary source of MSCs that are characterized
by self-renewable and replicating cells. However, several studies have reported that after a
certain number of serial subcultures, MSCs enter replicative senescence state and cease to
proliferate [12,32,40,41].
This study identified the differences between PD and control cells. These findings sup-
port the theory that neurodegenerative disease is related to cell senescence and cell viability.
By using the DAVID software, this study found that ECM-receptor related genes were
characteristically down-regulated in PD cells. Through SA-β-Gal positive cell counting and
Thio-S staining, our results suggest that the ECM molecule, Reelin, plays structurally and
functionally important roles in maintaining the cell viability, attenuating cell senescence,
and decreasing pathological α–Synuclein (α-Syn) levels. Based on our findings, in PD cells,
problems with this function might have some influence on the decreased cell viability and
difference in phenotype. Using RT-PCR and human recombinant protein experiments,
this study found that RELN, among the ECM receptor-related genes, was particularly
down-regulated by GEP investigation.
Reelin is an ECM glycoprotein that controls brain development by regulation of
neuronal migration and positioning [42]. Reelin also has an important role in brain devel-
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opment via its effects on neuronal migration, dendritogenesis, and synaptic transmission.
Homozygous Reeler mice, lacking RELN, are severely ataxic and have structural anomalies
in neocortical, hippocampal, and cerebellar structures [43,44]. The effects are less severe in
heterozygous Reeler mice; however, these animals do have problems with dendrite devel-
opment and cognitive function [45,46]. Reelin controls synaptic plasticity by influencing
long-term potentiation both during development and in adulthood [47,48], and contributes
to AD pathogenesis. Apolipoprotein E receptor 2 and very-low-density-lipoprotein (VLDL)
receptor, which are Reelin receptors, belong to the low-density-lipoprotein (LDL) receptor
gene family, and are referred to as the apolipoprotein E receptor [49]. Apolipoprotein E4,
an apolipoprotein E isoform, has an important role in AD pathogenesis [49,50]. According
to recent research, there are fewer Reelin-producing Cajal-Retzius cells in the first cortical
layer in patients with AD [51,52], and Reelin contributes to AD pathogenesis by controlling
synaptic glutamatergic transmission and potentiation [50,53]. Endocytosis and shuttling
mechanisms of intracellular aggregations with α-Syn burden are important subject to study
in PD. Many studies have focused on revealing the underlying mechanisms of impaired
endocytosis and lysosomal rupture in PD [54–56]. We also found the relationship between
α-Syn and vesicle associated membrane protein (VAMP2) [57]. However, the association
of ECM molecule, particularly glycoprotein Reelin, with α-Syn burden still need to be
explored further. Therefore, we selected ECM proteins to confirm whether they could be a
promising therapeutic target in PD.
In the present study, using transcriptome analysis, the down-regulation of ECM
receptor interaction-related genes was observed. Both RNA and protein expressions of
Reelin were significantly decreased in PD compared to the control cells at passage 8. The
differences in expression patterns determined by transcriptome analysis were confirmed
by RT-PCR, qRT-PCR, and Western blot. MSCs derived from a control individual and
a patient with PD were cultured from passage 4 to 8, during which the number of PD
MSCs decreased rapidly. In contrast, the number of control MSCs decreased rapidly
at passage 5. The SA-β-Gal staining of control MSCs at passages 4 and 8 was reduced
compared to PD, indicating higher rates of senescence of PC cells. To evaluate the effect
of Reelin in both control and PD cells, passage 8 MSCs from both groups were treated
with various concentrations of hr-Reelin proteins. The results showed that Reelin could
significantly induce proliferation and inhibit acceleration of cell senescence compared with
DPBS controls.
Abnormal accumulation and aggregation of α-Syn proteins are neuropathological
features of PD patients [58]. PFFs, which are aggregated form of α-Syn proteins, can induce
cell senescence and cell death [30,59,60]. In this study, we tested whether Reelin protein
could protect dopaminergic neurons from PFFs in SH-SY5Y cells model of PD. Thio-S
staining analysis showed that hr-Reelin effectively suppressed the α-Syn aggregations
that were induced by PFFs in SH-SY5Y cells. In line with these findings, we support the
hypothesis that Reelin has a beneficial effect to neuron cells in PD patients. Our study
found that Reelin could cause positive effects on ECM function, such as increasing cell
viability, decreasing cell senescence, and suppressing the α-Syn aggregation. Importantly,
these findings could assist in understanding PD pathogenesis and selecting treatment
targets; but first, further study is needed to confirm whether Reelin ECM molecule also
has beneficial effects in primary neuronal cell model and animal models of PD. Second,
uncovering how Reelin ECM molecule is involved in enhancing cell viability, attenuating
cell senescence, and reducing pathological α-Syn formation is also required in both primary
neuronal cell model and animal model of PD.
5. Conclusions
In this study, the GEP of MSCs on both PD cells and control group was analyzed.
RELN was among ECM-receptor-related genes whose expression was down-regulated in
PD, and hr-Reelin prevented PFF-induced α-Syn aggregation. A better understanding of
Genes 2021, 12, 1066 12 of 14
Reelin functions and regulation in PD are required to improve the prospects for successful
treatment of PD.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/genes12071066/s1, Figure S1: Cell viability of control and Parkinson’s disease (PD) cells at
passage 8 following treatment with either DPBS or various concentrations of human recombinant
Reelin (hr-Reelin) protein.
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13. Fričová, D.; Korchak, J.A.; Zubair, A.C. Challenges and translational considerations of mesenchymal stem/stromal cell therapy
for Parkinson’s disease. NPJ Regen. Med. 2020, 5, 20. [CrossRef] [PubMed]
14. Liu, Z.; Cheung, H.H. Stem Cell-Based Therapies for Parkinson Disease. Int. J. Mol. Sci. 2020, 21, 8060. [CrossRef]
Genes 2021, 12, 1066 13 of 14
15. Adams, B.; Nunes, J.M.; Page, M.J.; Roberts, T.; Carr, J.; Nell, T.A.; Kell, D.B.; Pretorius, E. Parkinson’s Disease: A Systemic
Inflammatory Disease Accompanied by Bacterial Inflammagens. Front. Aging Neurosci. 2019, 11, 210. [CrossRef]
16. Levy, O.A.; Malagelada, C.; Greene, L.A. Cell death pathways in Parkinson’s disease: Proximal triggers, distal effectors, and final
steps. Apoptosis 2009, 14, 478–500. [CrossRef]
17. Bonneh-Barkay, D.; Wiley, C.A. Brain extracellular matrix in neurodegeneration. Brain Pathol. 2009, 19, 573–585. [CrossRef]
18. Berezin, V.; Walmod, P.S.; Filippov, M.; Dityatev, A. Targeting of ECM molecules and their metabolizing enzymes and receptors
for the treatment of CNS diseases. Prog. Brain Res. 2014, 214, 353–388. [CrossRef]
19. Raghunathan, R.; Hogan, J.D.; Labadorf, A.; Myers, R.H.; Zaia, J. A glycomics and proteomics study of aging and Parkinson’s
disease in human brain. Sci. Rep. 2020, 10, 12804. [CrossRef]
20. Byeon, J.S.; Jeong, J.Y.; Kim, M.J.; Lee, S.M.; Nam, W.H.; Myung, S.J.; Kim, J.G.; Yang, S.K.; Kim, J.H.; Suh, D.J. Adiponectin and
adiponectin receptor in relation to colorectal cancer progression. Int. J. Cancer 2010, 127, 2758–2767. [CrossRef]
21. Ai, B.; Gao, Y.; Zhang, X.; Tao, J.; Kang, M.; Huang, H. Comparative transcriptome resources of eleven Primulina species, a group
of ‘stone plants’ from a biodiversity hot spot. Mol. Ecol. Resour. 2015, 15, 619–632. [CrossRef]
22. Won, Y.H.; Lee, M.Y.; Choi, Y.C.; Ha, Y.; Kim, H.; Kim, D.Y.; Kim, M.S.; Yu, J.H.; Seo, J.H.; Kim, M.; et al. Elucidation of Relevant
Neuroinflammation Mechanisms Using Gene Expression Profiling in Patients with Amyotrophic Lateral Sclerosis. PLoS ONE
2016, 11, e0165290. [CrossRef]
23. Lin, J.Q.; Zhao, X.X.; Zhi, Q.Q.; Zhao, M.; He, Z.M. Transcriptomic profiling of Aspergillus flavus in response to 5-azacytidine.
Fungal Genet. Biol. 2013, 56, 78–86. [CrossRef]
24. Lee, E.J.; Malik, A.; Pokharel, S.; Ahmad, S.; Mir, B.A.; Cho, K.H.; Kim, J.; Kong, J.C.; Lee, D.M.; Chung, K.Y.; et al. Identification
of genes differentially expressed in myogenin knock-down bovine muscle satellite cells during differentiation through RNA
sequencing analysis. PLoS ONE 2014, 9, e92447. [CrossRef]
25. Jiao, X.; Sherman, B.T.; Huang da, W.; Stephens, R.; Baseler, M.W.; Lane, H.C.; Lempicki, R.A. DAVID-WS: A stateful web service
to facilitate gene/protein list analysis. Bioinformatics 2012, 28, 1805–1806. [CrossRef]
26. Kanehisa, M.; Goto, S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000, 28, 27–30. [CrossRef]
27. Kanehisa, M.; Goto, S.; Sato, Y.; Furumichi, M.; Tanabe, M. KEGG for integration and interpretation of large-scale molecular data
sets. Nucleic Acids Res. 2012, 40, D109–D114. [CrossRef]
28. Lee, M.Y.; Yu, J.H.; Kim, J.Y.; Seo, J.H.; Park, E.S.; Kim, C.H.; Kim, H.; Cho, S.R. Alteration of synaptic activity-regulating genes
underlying functional improvement by long-term exposure to an enriched environment in the adult brain. Neurorehabil. Neural
Repair 2013, 27, 561–574. [CrossRef]
29. Volpicelli-Daley, L.A.; Luk, K.C.; Patel, T.P.; Tanik, S.A.; Riddle, D.M.; Stieber, A.; Meaney, D.F.; Trojanowski, J.Q.; Lee, V.M.
Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 2011, 72,
57–71. [CrossRef]
30. Rodríguez-Losada, N.; de la Rosa, J.; Larriva, M.; Wendelbo, R.; Aguirre, J.A.; Castresana, J.S.; Ballaz, S.J. Overexpression of α
-synuclein promotes both cell proliferation and cell toxicity in human SH-SY5Y neuroblastoma cells. J. Adv. Res. 2020, 23, 37–45.
[CrossRef]
31. Tan, F.C.; Hutchison, E.R.; Eitan, E.; Mattson, M.P. Are there roles for brain cell senescence in aging and neurodegenerative
disorders? Biogerontology 2014, 15, 643–660. [CrossRef] [PubMed]
32. Hayflick, L.; Moorhead, P.S. The serial cultivation of human diploid cell strains. Exp. Cell Res. 1961, 25, 585–621. [CrossRef]
33. Bree, R.T.; Stenson-Cox, C.; Grealy, M.; Byrnes, L.; Gorman, A.M.; Samali, A. Cellular longevity: Role of apoptosis and replicative
senescence. Biogerontology 2002, 3, 195–206. [CrossRef] [PubMed]
34. Coppé, J.-P.; Desprez, P.-Y.; Krtolica, A.; Campisi, J. The senescence-associated secretory phenotype: The dark side of tumor
suppression. Annu. Rev. Pathol. Mech. Dis. 2010, 5, 99–118. [CrossRef]
35. Gu, Y.; Li, T.; Ding, Y.; Sun, L.; Tu, T.; Zhu, W.; Hu, J.; Sun, X. Changes in mesenchymal stem cells following long-term culture
in vitro. Mol. Med. Rep. 2016, 13, 5207–5215. [CrossRef]
36. Zhang, P.; Shao, X.Y.; Qi, G.J.; Chen, Q.; Bu, L.L.; Chen, L.J.; Shi, J.; Ming, J.; Tian, B. Cdk5-Dependent Activation of Neuronal
Inflammasomes in Parkinson’s Disease. Mov. Disord. 2016, 31, 366–376. [CrossRef]
37. Sharma, R.; Kumar, D.; Jha, N.K.; Jha, S.K.; Ambasta, R.K.; Kumar, P. Re-expression of cell cycle markers in aged neurons and
muscles: Whether cells should divide or die? Biochim. Biophys. Acta Mol. Basis Dis. 2017, 1863, 324–336. [CrossRef]
38. Sah, E.; Krishnamurthy, S.; Ahmidouch, M.Y.; Gillispie, G.J.; Milligan, C.; Orr, M.E. The Cellular Senescence Stress Response in
Post-Mitotic Brain Cells: Cell Survival at the Expense of Tissue Degeneration. Life 2021, 11, 229. [CrossRef]
39. Levi, N.; Papismadov, N.; Solomonov, I.; Sagi, I.; Krizhanovsky, V. The ECM path of senescence in aging: Components and
modifiers. FEBS J. 2020, 287, 2636–2646. [CrossRef]
40. Truong, N.C.; Bui, K.H.; Van Pham, P. Characterization of Senescence of Human Adipose-Derived Stem Cells After Long-Term
Expansion. Adv. Exp. Med. Biol. 2019, 1084, 109–128. [CrossRef]
41. Liu, J.; Ding, Y.; Liu, Z.; Liang, X. Senescence in Mesenchymal Stem Cells: Functional Alterations, Molecular Mechanisms, and
Rejuvenation Strategies. Front. Cell Dev. Biol. 2020, 8, 258. [CrossRef]
42. In, C. Genetics Home Reference, Medlineplus. 2013. Available online: https://medlineplus.gov/genetics/gene/reln/ (accessed
on 13 August 2020).
Genes 2021, 12, 1066 14 of 14
43. Lambert de Rouvroit, C.; Goffinet, A.M. The reeler mouse as a model of brain development. Adv. Anat. Embryol Cell Biol. 1998,
150, 1–106.
44. D’Arcangelo, G. Reelin mouse mutants as models of cortical development disorders. Epilepsy Behav. 2006, 8, 81–90. [CrossRef]
45. Krueger, D.D.; Howell, J.L.; Hebert, B.F.; Olausson, P.; Taylor, J.R.; Nairn, A.C. Assessment of cognitive function in the heterozy-
gous reeler mouse. Psychopharmacology 2006, 189, 95–104. [CrossRef]
46. Niu, S.; Renfro, A.; Quattrocchi, C.C.; Sheldon, M.; D’Arcangelo, G. Reelin promotes hippocampal dendrite development through
the VLDLR/ApoER2-Dab1 pathway. Neuron 2004, 41, 71–84. [CrossRef]
47. D’Arcangelo, G. Apoer2: A reelin receptor to remember. Neuron 2005, 47, 471–473. [CrossRef]
48. Weeber, E.J.; Beffert, U.; Jones, C.; Christian, J.M.; Förster, E.; Sweatt, J.D.; Herz, J. Reelin and ApoE receptors cooperate to enhance
hippocampal synaptic plasticity and learning. J. Biol. Chem. 2002, 277, 39944–39952. [CrossRef]
49. Herz, J.; Beffert, U. Apolipoprotein E receptors: Linking brain development and Alzheimer’s disease. Nat. Rev. Neurosci. 2000, 1,
51. [CrossRef]
50. Herz, J.; Chen, Y. Reelin, lipoprotein receptors and synaptic plasticity. Nat. Rev. Neurosci. 2006, 7, 850. [CrossRef]
51. Baloyannis, S.J.; Costa, V.; Mauroudis, I.; Psaroulis, D.; Manolides, S.L.; Manolides, L.S. Dendritic and spinal pathology in the
acoustic cortex in Alzheimer’s disease: Morphological and morphometric estimation by Golgi technique and electron microscopy.
Acta Oto-Laryngol. 2007, 127, 351–354. [CrossRef]
52. Baloyannis, S.J. Morphological and morphometric alterations of Cajal-Retzius cells in early cases of Alzheimer’s disease: A Golgi
and electron microscope study. Int. J. Neurosci. 2005, 115, 965–980. [CrossRef] [PubMed]
53. Rice, D.S.; Curran, T. Role of the reelin signaling pathway in central nervous system development. Annu. Rev. Neurosci. 2001, 24,
1005–1039. [CrossRef] [PubMed]
54. Shin, N.; Jeong, H.; Kwon, J.; Heo, H.Y.; Kwon, J.J.; Yun, H.J.; Kim, C.H.; Han, B.S.; Tong, Y.; Shen, J.; et al. LRRK2 regulates
synaptic vesicle endocytosis. Exp. Cell Res. 2008, 314, 2055–2065. [CrossRef] [PubMed]
55. Dijkstra, A.A.; Ingrassia, A.; de Menezes, R.X.; van Kesteren, R.E.; Rozemuller, A.J.; Heutink, P.; van de Berg, W.D. Evidence for
Immune Response, Axonal Dysfunction and Reduced Endocytosis in the Substantia Nigra in Early Stage Parkinson’s Disease.
PLoS ONE 2015, 10, e0128651. [CrossRef] [PubMed]
56. Heaton, G.R.; Landeck, N.; Mamais, A.; Nalls, M.A.; Nixon-Abell, J.; Kumaran, R.; Beilina, A.; Pellegrini, L.; Li, Y.; Harvey, K.; et al.
Sequential screening nominates the Parkinson’s disease associated kinase LRRK2 as a regulator of Clathrin-mediated endocytosis.
Neurobiol. Dis. 2020, 141, 104948. [CrossRef]
57. Kim, K.; Wi, S.; Seo, J.H.; Pyo, S.; Cho, S.R. Reduced Interaction of Aggregated α-Synuclein and VAMP2 by Environmental
Enrichment Alleviates Hyperactivity and Anxiety in a Model of Parkinson’s Disease. Genes 2021, 12, 392. [CrossRef]
58. Duda, J.E.; Lee, V.M.; Trojanowski, J.Q. Neuropathology of synuclein aggregates. J. Neurosci. Res. 2000, 61, 121–127. [CrossRef]
59. Luk, K.C.; Song, C.; O’Brien, P.; Stieber, A.; Branch, J.R.; Brunden, K.R.; Trojanowski, J.Q.; Lee, V.M. Exogenous α -synuclein fibrils
seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc. Natl. Acad. Sci. USA 2009, 106, 20051–20056.
[CrossRef]
60. Marques, O.; Outeiro, T.F. α -synuclein: From secretion to dysfunction and death. Cell Death Dis. 2012, 3, e350. [CrossRef]
